SMMT

Summit Therapeutics Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 0/10
  • Value↑ 6/10
Summit Therapeutics sales and earnings growth
SMMT Growth
Low
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -366.67%
  • FCF Y/Y↓ -127.49%
Summit Therapeutics gross and profit margin trends
SMMT Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -289.01%
Summit Therapeutics net debt vs free cash flow
SMMT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Summit Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗